Merck announced positive Phase 2 trial data for zilovertamab vedotin, an investigational antibody-drug conjugate targeting ROR1, in combination with standard chemotherapy (R-CHP) for previously untreated diffuse large B-cell lymphomaB-cell lymphoma (DLBCL). The combination achieved a 100% complete response rate in patients treated with a 1.75 mg/kg dose of zilovertamab vedotin, leading to the establishment of this dose for the upcoming Phase 3 trial. This research aims to address the unmet need for more effective first-line DLBCL treatments, as approximately 40% of patients relapse or develop refractory disease after initial standard therapy.
For Merck, positive Phase 2 results increase the likelihood of successful Phase 3 trials and potential regulatory approval, representing a significant advancement in their oncology pipeline. For the DLBCL patient population, a new, effective treatment option could significantly improve outcomes and survival rates. This is particularly important given the aggressive nature of DLBCL and the limitations of current therapies in preventing relapse.
The Phase 2 waveLINE-007 trial enrolled 36 patients with previously untreated DLBCL. Three dosage arms of zilovertamab vedotin (1.75 mg/kg, 2.0 mg/kg, and 2.25 mg/kg) were evaluated in combination with R-CHP. All three arms showed high complete response rates (100%, 93.3%, and 100%, respectively). The overall complete response rate at the end of treatment was 97.2%. The median duration of response has not yet been reached. While the safety profile was manageable, serious treatment-related adverse events occurred in 11% of patients, and Grade 3-4 treatment-related adverse events occurred in 58% of patients, most commonly neutropenia, nausea, anemia, and diarrhea. The 1.75 mg/kg dose was chosen for Phase 3 due to its high efficacy and seemingly better tolerability.
The positive Phase 2 data suggests zilovertamab vedotin, in combination with R-CHP, holds promise as a potential first-line treatment for DLBCL. The upcoming Phase 3 trial will be crucial in confirming these findings in a larger patient population and further evaluating the long-term efficacy and safety profile. If successful, this therapy could become a valuable new option for patients with DLBCL, potentially improving survival rates and quality of life.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
